NCT01781338View on ClinicalTrials.gov

Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

4,936

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

September 30, 2020

Study Completion Date

January 15, 2025

Conditions

Breast Cancer

Interventions

OTHER

Induction therapy

The intervention is dependent on the respective sub-protocol and can include either endocrine therapy, neoadjuvant chemotherapy or targeted therapy.

Trial Locations (2)

41061

Ev. Krankenhaus Bethesda Brustzentrum Niederrhein, Mönchengladbach

81377

Breast Center of the University of Munich (LMU) Universitätsfrauenklinik Großhadern, Munich

All Listed Sponsors

lead

West German Study Group

OTHER

NCT01781338 - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer | Biotech Hunter | Biotech Hunter